NASAFYTOL^® supplementation in adults hospitalized with COVID-19 infection: results from an exploratory open-label randomized controlled trial.

ABSTRACT:

Objectives

The effect and safety of Nasafytol^®, a food supplement combining curcumin, quercetin, and Vitamin D, on hospitalized COVID-19-positive patients as support to standard of care were to be assessed.

Methods

This exploratory, open-label, randomized, controlled trial was carried out among hospitalized adults with COVID-19 infection. Participants were randomly assigned to receive Nasafytol^® or Fultium^® control. The improvement of the clinical condition and occurrence of (serious) adverse events were evaluated. The study was registered on clincaltrials.gov with the identifier NCT04844658.

Results

Twenty-five patients received Nasafytol^®, and 24 received Fultium^®. Demographic characteristics were well balanced

SUBMITTER: Gerain J 

PROVIDER: S-EPMC10324407 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature